Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Daniel W Sherbenou

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Sherbenou, Daniel

One or more keywords matched the following properties of Sherbenou, Daniel

Property

Value

overview

As an undergraduate at the University of Colorado, I started by scientific career focused on basic science research of cancer. In the laboratory of Dr. Min Han, I studied the Ras cell signaling pathway using the C. elegans model organism. In the MD/PhD program at Oregon Heath & Science University, I focused on translational leukemia research. Under the mentorship of Drs. Brian Druker and Michael Deininger, I focused on chronic myeloid leukemia. My thesis evaluated mechanisms of kinase inhibitor resistance in patients treated with imatinib (Gleevec). In oncology fellowship at University of California at San Francisco, I focused on the study of antibody-based therapeutics under the mentorship of Dr. Bin Liu. Antibody-drug conjugates (ADCs) are another rapidly growing approach to cancer treatment. With Dr. Liu, I conducting preclinical analyses of a novel ADC for multiple myeloma, with hope this this to soon lead to transition to the clinic. Now a faculty member at UC Denver in the Hematology division, I will oversee a translational research laboratory focused on novel therapy development and optimization for multiple myeloma and will care for patients with myeloma and related plasma cell disorders of Colorado and adjoining areas.

One or more keywords matched the following items that are connected to Sherbenou, Daniel

Item Type	Name
Concept	Multiple Myeloma
Academic Article	The development of potential antibody-based therapies for myeloma.
Award or Honor Receipt	Young Investigator Award - Grand Multiple Myeloma Translational Initiative
Academic Article	Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
Academic Article	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Academic Article	Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Academic Article	Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.
Academic Article	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Grant	Targeting Cancer Initiating Cells in Multiple Myeloma
Academic Article	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Academic Article	Disruption of IRE1a through its kinase domain attenuates multiple myeloma.
Academic Article	Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
Academic Article	Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Academic Article	Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Academic Article	Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Academic Article	Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
Academic Article	Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
Academic Article	Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.
Grant	Ex Vivo Sensitivity Testing for T Cell Engaging Bispecific Antibody Selection in Patients with Multiple Myeloma
Grant	Drug Susceptibilities of Multiple Myeloma Subpopulations in Multi-Drug Resistant Patients
Academic Article	CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
Academic Article	CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma.
Academic Article	CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts.
Academic Article	Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Academic Article	MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
Academic Article	Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.

Search Criteria

Multiple Myeloma